Drug interactions
Liposomal doxorubicin + Tofacitinib
Severity: Major
Liposomal doxorubicin and Tofacitinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs suppress immune function, and combining them raises the risk of serious infections. Tofacitinib labeling advises against use with potent immunosuppressants, and myelosuppressive chemotherapy adds to the risk.
What this interaction means in plain words
Liposomal doxorubicin and Tofacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Liposomal doxorubicin belongs to Oncology; Tofacitinib belongs to Musculoskeletal.
Why it happens
Additive immunosuppression and myelosuppression.
What to do
Avoid combining where possible; if unavoidable, monitor closely for infection and neutrophil and lymphocyte counts, and interrupt tofacitinib if serious infection develops.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Tofacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Tofacitinib
- Baricitinib + Tofacitinib Contraindicated
- Cladribine + Tofacitinib Contraindicated
- Tofacitinib + Upadacitinib Contraindicated
- Abatacept + Tofacitinib Major
- Anti-thymocyte + Tofacitinib Major
- Antithymocyte globulin equine + Tofacitinib Major
Frequently asked questions
Can I take Liposomal doxorubicin with Tofacitinib?
MediHelp rates the interaction as major. Liposomal doxorubicin and Tofacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs suppress immune function, and combining them raises the risk of serious infections. Tofacitinib labeling advises against use with potent immunosuppressants, and myelosuppressive chemotherapy adds to the risk.
How serious is the interaction between Liposomal doxorubicin and Tofacitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible; if unavoidable, monitor closely for infection and neutrophil and lymphocyte counts, and interrupt tofacitinib if serious infection develops.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
